referenceid	timestamp_started	timestamp_finished	nctid	reason_for_termination	primary_reason	secondary_reasons_1a	secondary_reasons_1b	secondary_reasons_1c	secondary_reasons_1d	secondary_reasons_1e	secondary_reasons_2a	secondary_reasons_2b	secondary_reasons_2c	secondary_reasons_2d	secondary_reasons_2e	secondary_reasons_3a	secondary_reasons_3b	secondary_reasons_none	open_text_1
367	2024-02-08 06:35:01	2024-03-11 08:53:56	NCT02067884	Slow accrual	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
1	2024-02-12 06:58:10	2024-02-27 04:09:01	NCT00150878	Insurance coverage reached	2e	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
2	2024-02-12 06:58:33	2024-02-27 04:10:07	NCT00480077	Low enrollment rates	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
3	2024-02-12 07:05:21	2024-03-11 08:54:42	NCT00618384	[No reason posted]	3a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
7	2024-02-12 07:13:08	2024-02-27 04:11:47	NCT00716833	poor recruitment	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
40	2024-02-12 07:16:31	2024-03-11 08:55:01	NCT00405873	Lack of efficacy	1c	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
5	2024-02-12 07:16:34	2024-02-27 04:11:05	NCT00672334	[No reason posted]	3a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
362	2024-02-12 07:17:49	2024-03-11 08:52:18	NCT01518465	Insufficient Accrual	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
364	2024-02-12 07:18:00	2024-03-11 08:52:51	NCT02127892	Closed due to slow accrual. Nine subjects enrolled over 7 years.	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
357	2024-02-12 07:19:25	2024-03-11 08:49:36	NCT00556907	Lack of Funding	2b	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
359	2024-02-12 07:19:32	2024-03-11 08:50:45	NCT02967380	Insufficient Accrual	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
355	2024-02-12 07:19:39	2024-03-11 08:49:00	NCT01801046	Insufficient Accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
127	2024-02-12 07:19:53	2024-02-27 05:22:44	NCT00950274	Recruitment stopped due to slow recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
4	2024-02-12 07:20:11	2024-02-27 04:10:31	NCT00640679	Due to slow enrollment the study was stopped prematurely.	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
8	2024-02-12 07:47:48	2024-02-27 04:12:11	NCT00798525	Supply of Lepirudin ended on 01. April 2012, thus trial terminated on 31. March 2012	2d	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
6	2024-02-27 04:11:13	2024-02-27 04:11:32	NCT00690118	The interim analysis showed no tendency in favour of the verum group. Therefore it was decided to stop the study prematurely.	1c	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
9	2024-02-27 04:12:16	2024-02-27 04:12:24	NCT00803309	At the end of the planned recruitment period the expected number of subjects could not be included in the trial.	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
10	2024-02-27 04:12:32	2024-02-27 04:12:46	NCT00986258	This clinical trial was terminated early, due to slow recruitment and study drug shortages.	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL
11	2024-02-27 04:12:54	2024-02-27 04:13:10	NCT00996554	Feasibility reasons; recruitment was too slow.	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL
12	2024-02-27 04:13:14	2024-02-27 04:13:57	NCT00999856	Two cohorts successfully completed; further cohorts not needed; no safety issue!	1b	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
13	2024-02-27 04:14:00	2024-02-27 04:14:12	NCT01021423	Terminated by sponsor due to new unpublished data that rendered the current design of the study no longer clinically relevant. There were no safety concerns.	1d	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
14	2024-02-27 04:14:17	2024-02-27 04:17:24	NCT01030666	shelf life of investigational drug ran out before 90 patients could be included	2d	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
15	2024-02-27 04:17:32	2024-02-27 04:17:44	NCT01143272	Masked independent interim analysis: completion of the trial was unlikely.	1c	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
16	2024-02-27 04:17:48	2024-02-27 04:17:55	NCT01178255	recruitment difficulties	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
17	2024-02-27 04:17:58	2024-02-27 04:18:35	NCT01239992	negative endpoint study resulting in withdrawal of study drug	1d	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
18	2024-02-27 04:18:38	2024-02-27 04:18:49	NCT01297712	enrollment terminated, analysis ongoing	3b	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
19	2024-02-27 04:18:52	2024-02-27 04:18:57	NCT01339026	Change in guidelines favouring newer antiplatelet drugs in ACS	1d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
20	2024-02-27 04:19:02	2024-02-27 04:19:16	NCT01564095	Missing evidence of the effectiveness of the study medication	1c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
21	2024-02-27 04:19:27	2024-02-27 04:19:58	NCT01601496	Slow Enrollment	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
22	2024-02-27 04:20:01	2024-02-27 04:20:07	NCT00626548	early efficacy review by the Independent Data Monitoring Committee indicated it was unlikely to meet its primary efficacy endpoints	1c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
23	2024-02-27 04:20:12	2024-02-27 04:20:19	NCT00746720	Patient recruitment difficulties	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
24	2024-02-27 04:20:23	2024-02-27 04:20:31	NCT00368121	Lack of recruitable patients	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
25	2024-02-27 04:20:34	2024-02-27 04:20:40	NCT00502554	insufficient patient recruitment and ECP capacity	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL
26	2024-02-27 04:20:45	2024-02-27 04:20:51	NCT00663104	[No reason posted]	3a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
27	2024-02-27 04:20:54	2024-02-27 04:21:01	NCT00667667	[No reason posted]	3a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
28	2024-02-27 04:21:09	2024-02-27 04:21:21	NCT00708942	Slow recruitment, study stopped with only 13 of 70 patients included in second part of the study	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
29	2024-02-27 04:21:30	2024-02-27 04:23:10	NCT00720850	Low recruitment, scientific rationale not applicable anymore to all patients and possible induction of GvHD by the study drug	1a	0	0	0	1	NULL	1	0	0	0	0	0	0	0	NULL
30	2024-02-27 04:23:14	2024-02-27 04:23:34	NCT00823290	Investigator left site	2c	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
31	2024-02-27 04:23:38	2024-02-27 04:23:44	NCT00933374	delayed recruitment	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
32	2024-02-27 04:23:48	2024-02-27 04:25:17	NCT01079091	The foundations of our pilotstudy planning has changed.	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	Other option is external evidence, but reason not clear (same as NCT01079104)
33	2024-02-27 04:25:20	2024-02-27 04:25:55	NCT01079104	The foundations of our pilotstudy planning has changed.	2e	0	0	0	0	NULL	0	0	0	0	0	0	0	1	Other option is external evidence, but reason not clear (same as NCT01079091)
34	2024-02-27 04:26:00	2024-02-27 04:26:47	NCT01187888	IMP used off label by phys. in pat. with PSP. Thus no more eligible patients were available for the study(pre-treatm.with Rasagiline=exclusion criterion	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	0	NULL	1	NULL
35	2024-02-27 04:26:58	2024-02-27 04:27:06	NCT01215266	Slow recruitment	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
36	2024-02-27 04:27:16	2024-02-27 04:27:29	NCT01245985	slow recruitment (only 8 patients recruited and treated until 12&#x2F;2012)	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
37	2024-02-27 04:27:33	2024-02-27 04:27:42	NCT00125606	insufficient patient recruitement	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
38	2024-02-27 04:27:46	2024-02-27 04:27:52	NCT00331721	Scientific data called into question the viability of the substance class	1d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
39	2024-02-27 04:28:09	2024-02-27 04:28:17	NCT00368264	Failure to recruit patients with membranous lupus nephritis not previously treated with azathioprine .	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
41	2024-02-27 04:28:21	2024-02-27 04:28:37	NCT00457951	Interim analysis: safety without efficacy ODSH in patients with acute COPD.	1c	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
42	2024-02-27 04:28:41	2024-02-27 04:28:47	NCT00511160	Study suspended due to logistical&#x2F;personnel difficulties	2e	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
43	2024-02-27 04:28:50	2024-02-27 04:28:57	NCT00586794	[No reason posted]	3a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
44	2024-02-27 04:29:00	2024-02-27 04:29:06	NCT00623415	[No reason posted]	3a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
45	2024-02-27 04:29:10	2024-02-27 04:29:14	NCT00628797	lack of recruitement	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
46	2024-02-27 04:29:18	2024-02-27 04:30:11	NCT00647192	Inclusion rate too low. Recruitment of further study centers too costly.	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
47	2024-02-27 04:30:14	2024-02-27 04:32:45	NCT00663455	Recruitment goals were not achieved. Extension of the trial concept had to be abjected due to methodological reasons.	2a	0	0	0	0	NULL	0	0	0	0	0	0	1	0	NULL
48	2024-02-27 04:32:49	2024-02-27 04:32:54	NCT00682747	poor recruitment	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
49	2024-02-27 04:32:57	2024-02-27 04:33:03	NCT00691912	Study was stopped due because recrutation.was much slower as anticipated.	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
50	2024-02-27 04:33:06	2024-02-27 04:33:20	NCT00704002	[No reason posted]	3a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
51	2024-02-27 04:33:34	2024-02-27 04:33:41	NCT00776191	al study sites stoped on 15&#x2F;05&#x2F;2012 because of insufficient recrutement.	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
52	2024-02-27 04:33:44	2024-02-27 04:33:50	NCT00806468	lack of recruitment	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
53	2024-02-27 04:33:53	2024-02-27 04:33:58	NCT00823225	Insufficient recruitment of study patients	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
54	2024-02-27 04:34:01	2024-02-27 04:34:08	NCT00852059	Diffculties to recruit anticipated study size, now analysis	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
55	2024-02-27 04:34:12	2024-02-27 04:34:23	NCT00866684	Insufficient patient recruitment	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
56	2024-02-27 04:34:25	2024-02-27 04:34:29	NCT00881257	Data was inconclusive	1c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
57	2024-02-27 04:34:35	2024-02-27 04:34:40	NCT00887276	[No reason posted]	3a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
58	2024-02-27 04:34:43	2024-02-27 04:35:41	NCT00930241	logistic reasons (insufficient funding, technical problems with MEMS)	2b	0	0	0	0	NULL	0	0	0	0	1	0	0	0	NULL
59	2024-02-27 04:35:44	2024-02-27 04:35:48	NCT00932724	The sponsor declared the early termination of the study due to poor recruitment of patients.	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
60	2024-02-27 04:35:52	2024-02-27 04:35:58	NCT00939939	Recruitment failure	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
61	2024-02-27 04:36:01	2024-02-27 04:36:06	NCT00967343	[No reason posted]	3a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
62	2024-02-27 04:36:09	2024-02-27 04:36:16	NCT01058369	Insufficient patient recruitment (only 2 patients)	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
63	2024-02-27 04:36:19	2024-02-27 04:36:25	NCT01058759	The external funding (pharmaceutical company) was stopped and could not be substituded by internal funding.	2b	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
64	2024-02-27 04:36:29	2024-04-15 07:36:02	NCT01069601	End of H1N1 Swine Flu Pandemic	3b	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
65	2024-02-27 04:38:20	2024-02-27 04:38:26	NCT01069965	Funding support withdrawn.	2b	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
66	2024-02-27 04:38:28	2024-02-27 04:38:36	NCT01071135	Planned number of 30 subjects could not be recruited during recruitment phase.	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
67	2024-02-27 04:38:38	2024-02-27 04:38:44	NCT01088256	[No reason posted]	3a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
68	2024-02-27 04:38:46	2024-02-27 04:38:51	NCT01088308	No enrollements for more than 6 months in Phase II	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
69	2024-02-27 04:38:53	2024-02-27 04:44:02	NCT01098565	The goal of collecting proof-of-concept information was met through additional modeling studies, new published evidence and information collected from the study	1b	0	0	0	0	NULL	0	0	0	0	0	0	0	0	This is another case for an early trial (phase 1 or 2) whcih has been terminated early as sufficient information has been collected; I categorized them now as &quot;Evidence of benefit&quot;, but it is rather enough evidence gather to answer the safety question
70	2024-02-27 04:44:25	2024-02-27 04:44:29	NCT01109966	[No reason posted]	3a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
71	2024-02-27 04:44:32	2024-02-27 04:44:37	NCT01199133	Following the DSMB recommendation. Study population being insufficiently symptomatic to enable differentiation between treatment and placebo. No safety concerns	1c	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
72	2024-02-27 04:44:44	2024-02-27 04:44:48	NCT01199783	Patient number to be enrolled not reachable in prospected time frame, decision to stop the study prematurely was made.	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
73	2024-02-27 04:44:52	2024-02-27 04:47:25	NCT01231854	delayed start of the trial, both treatment options already have market authorizations, study medication expired	2e	0	0	0	0	NULL	0	0	0	1	1	0	0	0	Not sure, market authorisation could be based on external evidence; otherwise a market authorisation would not necessarily make the study unnecessary. 
74	2024-02-27 04:47:30	2024-02-27 04:54:00	NCT01298830	Need for improvement of study medication. Safety data collected sufficient. No further gain in knowledge expected.	1a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	recategorize
75	2024-02-27 04:54:07	2024-02-27 04:54:16	NCT01320280	unexpectedly slow recruitment	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
76	2024-02-27 04:54:22	2024-02-27 04:54:28	NCT01341340	Discontinued due to poor enrollment. Insufficient number of patients enrolled to permit a statistically rigorous assessment of safety and efficacy.	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
77	2024-02-27 04:54:32	2024-02-27 04:54:38	NCT01357460	difficult patient recruitment	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
78	2024-02-27 04:54:41	2024-02-27 04:54:45	NCT01363921	insufficient patient recruiting	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
79	2024-02-27 04:54:48	2024-02-27 04:54:54	NCT01367691	[No reason posted]	3a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
80	2024-02-27 04:54:58	2024-02-27 04:55:05	NCT01374789	The study was terminated due to insufficient recruitment.	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
81	2024-02-27 04:55:08	2024-02-27 04:55:14	NCT01409850	Very slow enrollment of participants	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
82	2024-02-27 04:55:18	2024-02-27 04:55:25	NCT01410903	inadequately recruitment rate, funding is not secured	2a	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	NULL	NULL
83	2024-02-27 04:55:28	2024-02-27 04:55:31	NCT01434914	early termination due to poor recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
84	2024-02-27 04:55:34	2024-02-27 04:55:39	NCT01447758	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
85	2024-02-27 04:55:42	2024-02-27 04:55:46	NCT01458015	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
86	2024-02-27 04:55:50	2024-02-27 04:55:53	NCT01531764	The recruitment was discontinued because of failure to meet expected enrolment goals	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
87	2024-02-27 04:55:58	2024-02-27 04:56:02	NCT01551407	slow inclusion rate	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
88	2024-02-27 04:56:09	2024-02-27 04:56:42	NCT01571895	Lack of efficacy observed at 1&#x2F;3 of the enrollment at investigated dosage. No results available.	1c	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
89	2024-02-27 04:56:45	2024-02-27 04:56:51	NCT01638585	recruition number was not reached	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
90	2024-02-27 04:56:53	2024-02-27 04:56:58	NCT01701843	prematurely terminated because of low recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
91	2024-02-27 04:57:02	2024-02-27 04:57:06	NCT01740544	[No reason posted]	3a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
92	2024-02-27 04:57:09	2024-02-27 04:57:13	NCT02188212	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
93	2024-02-27 04:57:15	2024-02-27 04:57:19	NCT00839059	Results of an interim analysis and a hardly ongoing enrolment in the last 10 months in all six participating centres	1c	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL
94	2024-02-27 04:57:22	2024-04-15 07:36:29	NCT01476553	Prematurely halted after interim data analysis	1e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	I checked the results publication https://pubmed.ncbi.nlm.nih.gov/30185117/ 
95	2024-02-27 05:02:34	2024-02-27 05:02:38	NCT01589211	Necessary number of participants not achieved and high drop out rate	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
96	2024-02-27 05:02:41	2024-02-27 05:02:44	NCT01352702	Slow recruitment; Study was terminated for futility reasons	1c	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL
97	2024-02-27 05:02:47	2024-02-27 05:02:50	NCT02207582	no efficacy	1c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
98	2024-02-27 05:06:20	2024-02-27 05:06:24	NCT02372318	Anticipated nr of 25 probands was not reached in terms of full data sets (missing data, low fMRI data quality), but time frame for recruitment ended.	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL
99	2024-02-27 05:07:22	2024-02-27 05:08:04	NCT02129400	The analysis of the blood samples was much expensive than calculated. The recruitment had to be stopped after 36 study participants.	2b	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
100	2024-02-27 05:08:07	2024-02-27 05:08:11	NCT02135926	Results from other RCT made randomization unethical.	1d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
101	2024-02-27 05:08:15	2024-04-15 07:36:42	NCT01817738	Follow up period after primary analysis was prematurely stopped because more mature data will not impact the study outcome	1e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	recategorize , Phase1/2 trial: sufficient (safety) information collected, a new category might be needed
102	2024-02-27 05:11:47	2024-02-27 05:12:19	NCT02034279	Low recruitment rate and expiration of the study drug	2a	0	0	0	0	NULL	0	0	0	1	0	0	0	0	NULL
103	2024-02-27 05:12:24	2024-02-27 05:12:28	NCT02340299	Slow recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
104	2024-02-27 05:12:32	2024-02-27 05:12:35	NCT01647880	delayed recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
105	2024-02-27 05:12:39	2024-02-27 05:12:42	NCT01440062	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
106	2024-02-27 05:12:46	2024-02-27 05:12:50	NCT01402739	Study terminated prematurely due to futility	1c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
107	2024-02-27 05:12:56	2024-02-27 05:13:00	NCT01111448	Unfavourable Risk-Benefit-Ratio	1a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
108	2024-02-27 05:13:04	2024-02-27 05:13:07	NCT02078986	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
109	2024-02-27 05:13:10	2024-02-27 05:13:14	NCT01569412	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
110	2024-02-27 05:13:18	2024-02-27 05:13:29	NCT01067703	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
111	2024-02-27 05:13:34	2024-02-27 05:13:37	NCT01853384	based on outcome of trial NCT01656889.	1d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
112	2024-02-27 05:13:42	2024-02-27 05:13:46	NCT01148264	poor enrolment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
113	2024-02-27 05:13:53	2024-02-27 05:13:57	NCT01203228	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
114	2024-02-27 05:14:00	2024-02-27 05:14:06	NCT02384850	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
115	2024-02-27 05:14:09	2024-02-27 05:14:13	NCT01900327	Recruitment failure	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
116	2024-02-27 05:14:19	2024-02-27 05:14:37	NCT01405417	not enough data collected	2e	0	0	0	0	NULL	0	0	0	0	0	0	0	1	I am not sure, but they have included 70 patients, so it might be a rather administrative reason why they have not collected sufficient data
117	2024-02-27 05:14:40	2024-02-27 05:14:44	NCT01931592	One of the study drugs was no longer available on a worldwide level.	2d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
118	2024-02-27 05:14:48	2024-02-27 05:14:51	NCT01852526	device failure	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
119	2024-02-27 05:14:54	2024-04-15 07:38:08	NCT02699034	Recommendation by BfArM after interim analysis	1e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	recategorize
120	2024-02-27 05:19:44	2024-02-27 05:21:50	NCT02380937	The study was terminated prematurely on 05May 2015 because of the unavailability of study devices.	2d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
121	2024-02-27 05:21:56	2024-02-27 05:22:00	NCT00923793	Recruitment was stopped, due to slow recruitment rate	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
122	2024-02-27 05:22:04	2024-02-27 05:22:08	NCT01534455	very slow patient recruitment and concerns about the actuality of the study design	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL
123	2024-02-27 05:22:13	2024-02-27 05:22:16	NCT02424552	recruitment problems	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
124	2024-02-27 05:22:20	2024-02-27 05:22:24	NCT01679405	No sufficient clinical or molecular signals for efficacy were observed.	1c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
125	2024-02-27 05:22:27	2024-02-27 05:22:30	NCT01841632	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
126	2024-02-27 05:22:34	2024-02-27 05:22:37	NCT01540344	Slow recruitment.	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
128	2024-02-27 05:22:51	2024-02-27 05:23:07	NCT02052193	Second cohort not opened because Simon-Two_Step model failed	1c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	 A small group of patients are enrolled in the first stage; and the enrollment of another group of patients in stage 2 is “conditional” on the outcome of the first group.
129	2024-02-27 05:23:16	2024-02-27 05:23:20	NCT01055522	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
130	2024-02-27 05:23:23	2024-02-27 05:23:29	NCT02820519	Intolerable high amount of adverse events	1a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
131	2024-02-27 05:23:34	2024-02-27 05:24:49	NCT01532453	For futility reasons and potential &quot;loss of chance&quot; for MD 3511356 group	1c	0	0	0	0	NULL	0	0	0	0	0	0	1	0	IMP 3511356 
132	2024-02-27 05:24:52	2024-02-27 05:26:21	NCT03854942	Recruitment rate could not be met in the study period, review group was dissolved before regular end of study. Recruitment was therefore terminated.	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL
133	2024-02-27 05:26:26	2024-02-27 05:26:29	NCT02585752	Low recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
134	2024-02-27 05:26:33	2024-02-27 05:26:37	NCT02539680	insufficiant recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
135	2024-02-27 05:26:40	2024-02-27 05:26:44	NCT02077309	bad recruitment of suitable participants, just 4 patients in one year	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
136	2024-02-27 05:26:47	2024-02-27 05:26:50	NCT01941550	Investigator left the site. Site closed.	2c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
137	2024-02-27 05:26:53	2024-02-27 05:26:56	NCT01888796	bad recruitment of suitable participants, just 8 patients in one year	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
138	2024-02-27 05:26:59	2024-02-27 05:27:03	NCT01341106	insufficient patient numbers have been recruited	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
139	2024-02-27 05:27:05	2024-02-27 05:27:09	NCT01266187	Recruitment difficulities	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
148	2024-02-27 13:04:30	2024-03-04 06:56:54	NCT01370044	results of interim analysis (not safety relevant)	1c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
140	2024-03-04 06:52:01	2024-03-04 06:52:41	NCT01262729	Feasibility and Recruitment problems	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	Does feasibility  mean anything more here?
141	2024-03-04 06:52:46	2024-03-04 06:52:55	NCT01242956	Problem to recruit sufficient patient number	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
142	2024-03-04 06:52:59	2024-03-04 06:53:03	NCT02475252	Recruitment too slow; study completion not possible within frame	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
143	2024-03-04 06:53:08	2024-03-04 06:53:17	NCT01402414	Difficulties with the Recruitement	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
144	2024-03-04 06:53:20	2024-03-04 06:54:15	NCT01563614	No patients can be recruited for this trial anymore due to other therapeutical approaches that became available.	1d	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
145	2024-03-04 06:54:20	2024-03-04 06:56:24	NCT02726048	Fisher &amp; Paykel Healthcare placed an administrative hold on the Simplus and Eson Non-Invasive Ventilation Evaluation study being conducted at Charite, Berlin	2e	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
146	2024-03-04 06:56:28	2024-03-04 06:56:33	NCT02019498	Recruitment problems	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
147	2024-03-04 06:56:36	2024-03-04 06:56:43	NCT01523938	[No reason posted]	3a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
149	2024-03-04 06:56:58	2024-03-04 06:57:06	NCT01259830	[No reason posted]	3a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
150	2024-03-04 06:57:45	2024-03-04 06:59:24	NCT02157363	poor recruitment due to change of surgical technique	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
151	2024-03-04 06:59:29	2024-03-04 06:59:34	NCT01146821	Low enrollment&#x2F; expiration of the grant	2a	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	NULL	NULL
152	2024-03-04 06:59:37	2024-03-04 06:59:41	NCT02595840	Futility	1c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
153	2024-03-04 06:59:46	2024-03-04 06:59:51	NCT02541357	Recruitment insufficient	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
154	2024-03-04 06:59:54	2024-03-04 06:59:58	NCT02488694	unsufficient recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
155	2024-03-04 07:00:02	2024-03-04 07:00:06	NCT02185703	Too slow recruitment rate	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
156	2024-03-04 07:00:11	2024-03-04 07:00:16	NCT02150473	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
157	2024-03-04 07:00:19	2024-03-04 07:00:23	NCT01755871	lack of recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
158	2024-03-04 07:00:31	2024-03-04 07:00:35	NCT00977132	delayed recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
159	2024-03-04 07:00:38	2024-03-04 07:00:42	NCT01176214	slow recruitment of patients	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
160	2024-03-04 07:00:48	2024-03-04 07:00:51	NCT02081053	Difficulty Enrolling	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
161	2024-03-04 07:00:55	2024-03-04 07:00:59	NCT00945126	Poor accrural	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
162	2024-03-04 07:01:02	2024-03-04 07:01:05	NCT00711542	Slow recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
163	2024-03-04 07:01:18	2024-03-04 07:01:25	NCT01690572	recruitment was not sufficient.	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
164	2024-03-04 07:01:38	2024-03-04 07:02:29	NCT01517776	due to an altered benefit&#x2F;risk assessment.	1a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
165	2024-03-04 07:02:33	2024-03-04 07:02:37	NCT01060423	Terminated due to poor subject enrolment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
166	2024-03-04 07:02:41	2024-03-04 07:02:45	NCT01045512	unsufficient recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
167	2024-03-04 07:02:49	2024-03-04 07:02:52	NCT02818959	Due to inability to recruit sufficient sample size in reasonable time frame.	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
168	2024-03-04 07:02:56	2024-03-04 07:03:34	NCT02606799	No further recruitment possible due to changed conditions	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
169	2024-03-04 07:03:38	2024-03-04 07:03:41	NCT02417103	Recruiting failure	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
170	2024-03-04 07:03:44	2024-03-04 07:04:33	NCT02071511	The Sponsor appreciate the devastating impact that the results of the SYMPLICITY HTN 3 trial had on research progress for renal denervation. Based on the lack of recent progress, it is no longer practical to maintain the agreement.	1d	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
171	2024-03-04 07:04:38	2024-03-04 07:04:41	NCT01887041	Recruiting problems	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
172	2024-03-04 07:04:45	2024-03-04 07:04:47	NCT01759238	unexpectedly slow recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
173	2024-03-04 07:04:54	2024-03-04 07:04:57	NCT01021202	unexpectedly slow recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
174	2024-03-04 07:05:00	2024-03-11 08:56:06	NCT00858793	A leukaemia case was reported in patient treated with a similar vector. For safety risk we stopped recruitment	1d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
175	2024-03-04 07:05:49	2024-03-04 07:05:54	NCT02728453	Insufficient recruitment.	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
176	2024-03-04 07:05:55	2024-03-04 07:05:59	NCT02374567	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
177	2024-03-04 07:06:07	2024-03-04 07:06:11	NCT01336530	The study stopped prematurely due to and administrative reasons, not based on grounds of safety.	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
178	2024-03-04 07:06:16	2024-03-04 07:06:19	NCT01117662	The planned recruitment number of 180 Patient could not been achieved.	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
179	2024-03-04 07:06:23	2024-03-04 07:08:07	NCT02772146	After 2 patients it was concluded that a large change in exclusion criteria and study design was needed to obtain the ojective for the study	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
180	2024-03-04 07:08:11	2024-04-15 07:38:46	NCT02130128	Sufficient clinical evidence was gathered	1e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	1e. Sufficient (safety) information collected
181	2024-03-04 07:10:31	2024-03-04 07:11:21	NCT01666600	Interim Analysis for Feasibility	1c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
182	2024-03-04 07:11:26	2024-03-04 07:11:29	NCT01617980	Slow accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
183	2024-03-04 07:11:37	2024-03-04 07:11:40	NCT01362582	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
184	2024-03-04 07:11:43	2024-03-04 07:11:45	NCT00753441	Low patient accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
185	2024-03-04 07:11:49	2024-03-04 07:11:51	NCT01522612	poor accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
186	2024-03-04 07:11:56	2024-03-04 07:11:58	NCT02641782	Antibody supply was discontinued by United Therapeutics Corporation.	2d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
187	2024-03-04 07:12:02	2024-03-04 07:12:04	NCT02891863	Futility	1c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
188	2024-03-04 07:12:16	2024-03-04 07:12:18	NCT02523859	Poor recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
189	2024-03-04 07:12:21	2024-03-04 07:12:24	NCT00595647	insufficient enrollment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
190	2024-03-04 07:12:29	2024-03-04 07:12:31	NCT02039167	The recruitment rate was very poor. The study was stopped by amendment on 2015-08-28.	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
191	2024-03-04 07:12:35	2024-03-04 07:12:37	NCT02594332	recruitment problems	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
192	2024-03-04 07:12:40	2024-03-04 07:15:03	NCT01340690	The sample size of the planned interims analysis was achieved	3b	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
193	2024-03-04 07:15:20	2024-03-04 07:15:23	NCT00659867	Recruitment problems	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
194	2024-03-04 07:15:27	2024-03-04 07:15:30	NCT02312479	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
195	2024-03-04 07:15:32	2024-03-04 07:16:14	NCT00834314	extended obligations of amended medical device law in Germany 2010 did not allow to continue and complete the trial due to budget limitation	2b	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
196	2024-03-04 07:16:17	2024-03-04 07:18:02	NCT02675816	Study halted due to low recruitment. Reimbursement changes require a larger study with additional centers and therefore, a new study planned as replacement.	2a	0	0	0	0	NULL	0	0	0	0	0	0	1	0	NULL
197	2024-03-04 07:18:07	2024-03-04 07:18:09	NCT02139098	Recruiting problems because of the time expenditure required for participating and the strict criteria of inclusion and exclusion	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
198	2024-03-04 07:18:12	2024-03-04 07:18:15	NCT02207309	poor recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
199	2024-03-04 07:18:20	2024-03-04 07:19:24	NCT01690325	Therapy of HER2+ patients according to protocol was no longer appropriate. Patient enrolment behind planned schedule and challenges of site performance	1d	0	0	0	0	NULL	1	0	0	0	1	0	0	0	NULL
200	2024-03-04 07:19:28	2024-03-04 07:20:14	NCT01439958	Core study 12011.201 was terminated.	3b	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
201	2024-03-04 07:20:18	2024-03-04 07:20:21	NCT01419002	lack of recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
202	2024-03-04 07:20:29	2024-03-04 07:20:34	NCT01407679	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
203	2024-03-04 07:20:38	2024-03-04 07:23:32	NCT01303250	The final decision of the review of HES-containing solution shall be awaited.	1d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	HES-containing solutions were suspended from the market, https://www.ema.europa.eu/en/news/hydroxyethyl-starch-solutions-infusion-recommended-suspension-market
204	2024-03-04 07:23:38	2024-03-04 07:23:41	NCT00413127	Less patients than expected for inclusion, therefore patient recruitment is to low	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
205	2024-03-04 07:23:44	2024-03-04 07:23:47	NCT02058810	Lack of patients, PI left	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	NULL
206	2024-03-04 07:23:51	2024-03-04 07:25:56	NCT02739685	Slow enrollment, access to devices	2a	0	0	0	0	NULL	0	0	0	1	0	0	0	0	NULL
207	2024-03-04 07:26:02	2024-03-04 07:26:05	NCT02632292	Slow enrollment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
208	2024-03-04 07:26:08	2024-03-04 07:26:12	NCT01312623	Terminated, because it is not possible to recruit enough participants	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
209	2024-03-04 07:26:15	2024-03-04 07:26:17	NCT02140138	Recruitment was terminated after enrolment of 35 instead of 36 evaluable patients for administrative reasons.	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
210	2024-03-04 07:26:20	2024-03-04 07:26:23	NCT01683864	Recruitment problems	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
211	2024-03-04 07:26:25	2024-03-04 07:26:27	NCT01582048	slow enrollment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
212	2024-03-04 07:26:33	2024-03-04 07:26:35	NCT01289938	To unsuccessful recruitment of rare UM-genotype. All other planned genotype groups are completed (EM, IM and PM).	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
213	2024-03-04 07:26:39	2024-03-04 07:26:41	NCT00961142	slow recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
214	2024-03-04 07:26:46	2024-03-11 08:56:30	NCT02198482	development program of study drug volasertib was stopped by Boehringer Ingelheim due to manufacturing problems	2d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
215	2024-03-04 07:27:16	2024-03-04 07:27:19	NCT01837082	Insufficient recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
216	2024-03-04 07:27:22	2024-03-04 07:27:24	NCT01397149	Insufficient recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
217	2024-03-04 07:27:32	2024-03-04 07:27:35	NCT01611207	The patient recruitment was behind target, no successful completion of the planned patient numbers within trial period could be expected	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
218	2024-03-04 07:27:37	2024-03-04 07:27:39	NCT01165450	Drug manufacturer could not supply study drug.	2d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
219	2024-03-04 07:27:43	2024-03-04 07:27:45	NCT00506909	Break in funding	2b	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
220	2024-03-04 07:27:49	2024-03-04 07:27:51	NCT00470548	Practice patterns with pemetrexed have evolved.	1d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
221	2024-03-04 07:27:54	2024-03-04 07:28:07	NCT01614067	Slow enrollment resulted in withdraw of funding	2a	0	0	0	0	NULL	0	1	0	0	0	0	0	0	NULL
222	2024-03-04 07:28:14	2024-03-04 07:28:16	NCT01061671	Futility	1c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
223	2024-03-04 07:28:19	2024-03-04 07:28:55	NCT02566278	Data collection has been halted. We are not recruiting any more subjects.	3b	0	0	0	0	NULL	0	0	0	0	0	0	0	1	no proper reason given why collection halted
224	2024-03-04 07:30:02	2024-03-04 07:30:05	NCT01373918	The study was terminated due to slow enrollment.	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
225	2024-03-04 07:30:07	2024-03-04 07:30:10	NCT02120027	Because of negative results of the sister study NAK-06 and the low overall response rate at week 24.	1d	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL
226	2024-03-04 07:30:13	2024-03-04 07:30:16	NCT01963403	Futility of recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
227	2024-03-04 07:30:19	2024-03-04 07:33:14	NCT01123161	The ICTuS 2 portion of the trial has been halted and data will be analyzed.	3b	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	 evidence of harm based on the publication: https://pubmed.ncbi.nlm.nih.gov/27834742/
228	2024-03-04 07:32:14	2024-03-04 07:34:44	NCT01261299	Contract ended	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
229	2024-03-04 07:34:50	2024-03-04 07:34:52	NCT02605304	The study experienced enrollment difficulties.	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
230	2024-03-04 07:35:00	2024-03-04 07:35:03	NCT02215161	Risk to benefit ratio is not acceptable	1a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
231	2024-03-04 07:35:10	2024-03-04 07:35:19	NCT02428309	Due to participant recruitment feasibility	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
232	2024-03-04 07:36:48	2024-04-15 07:39:09	NCT01116661	The primary objective for high grade gliomas has been met and the FDA has now approved the drug (Gleolan) for use in the United States.	1b	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	1e. Sufficient (safety) information collected
233	2024-03-04 07:37:19	2024-03-04 07:37:22	NCT02147301	Risk to benefit ratio is not acceptable	1a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
234	2024-03-04 07:37:27	2024-03-04 07:39:35	NCT02444793	The study was terminated due to marginal efficacy and change in sponsor prioritization. The combination had a manageable safety profile.	1c	0	0	0	0	NULL	0	0	0	0	1	0	0	0	NULL
235	2024-03-04 07:40:21	2024-03-04 07:40:23	NCT02465983	Lack of efficacy and funding to continue investigation	1c	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	NULL	NULL
236	2024-03-04 07:40:27	2024-03-04 07:40:40	NCT02205307	Slow recruitment	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
237	2024-03-04 07:40:43	2024-03-04 07:40:49	NCT02254902	Changes in funding status	2b	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
238	2024-03-04 07:40:54	2024-03-04 07:41:19	NCT01601626	The study was stopped early due to feasibility concerns.	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
239	2024-03-04 07:42:04	2024-03-04 07:42:09	NCT01098422	Halted due to slow enrollment	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
240	2024-03-04 07:42:12	2024-03-04 07:42:15	NCT02093962	At the interim analysis, the futility boundary was not met and the study was stopped due to insufficient efficacy.	1c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
241	2024-03-04 07:42:20	2024-04-15 07:41:00	NCT02508441	Part 1 of the study was completed and the maximum tolerated dose determined. Part 2 of the study was terminated and will be conducted under a new protocol.	3b	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	I wonder if it is a real terminated trial as the first part has been completed; I would classify this under a new category &quot;Sufficient (safety) information collected&quot;
242	2024-03-04 07:43:12	2024-03-04 07:43:16	NCT01562132	Stopped in accordance with pre-specified stopping rules for poor recruitment.	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
243	2024-03-04 07:43:20	2024-03-04 07:43:22	NCT01841307	Difficulty recruiting; Funding ended; interim analysis provided sufficient data for interpretation.	2a	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	NULL	NULL
244	2024-03-04 07:43:25	2024-03-04 07:43:27	NCT01313923	Lack of funding	2b	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
245	2024-03-04 07:43:32	2024-03-04 07:43:35	NCT01510756	slow enrollment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
246	2024-03-04 07:43:38	2024-03-04 07:43:40	NCT01838499	At the planned IA for decision making, no evidence was demonstrated of MEDI8968 activity in reducing (HS) severity or pain over that seen with placebo.	1c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
247	2024-03-04 07:43:48	2024-03-04 07:43:54	NCT01391949	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
248	2024-03-04 07:44:01	2024-03-04 07:44:04	NCT02046928	Slow enrollment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
249	2024-03-04 07:44:08	2024-03-04 07:44:11	NCT02327637	Low recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
250	2024-03-04 07:44:17	2024-03-04 07:44:20	NCT00771862	Could not secure funding to complete the study.	2b	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
251	2024-03-04 07:44:24	2024-03-04 07:44:28	NCT02644122	Slow enrollment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
252	2024-03-04 07:44:33	2024-03-04 07:44:36	NCT02177773	FDA approved agent for this indication during enrollment	1d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
253	2024-03-04 07:44:39	2024-03-04 07:44:42	NCT02078895	The study was terminated due to low enrollment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
254	2024-03-04 07:44:45	2024-03-04 07:44:48	NCT02591381	Study was started but closed prior to completion because we could not meet enrollment numbers	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
255	2024-03-04 07:44:54	2024-03-04 07:45:10	NCT02719730	Change in study design to be a pilot with no randomization to intervention&#x2F;control	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	I wonder why a change in study design leads to a terminated trial and not a protocol change
256	2024-03-04 07:45:16	2024-03-04 07:45:22	NCT02317276	Unable to meet the study&#x27;s recruitment goals	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
257	2024-03-04 07:45:37	2024-03-04 07:46:22	NCT02634606	Unable to obtain supplement for this study. Unable to recruit.	2d	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	NULL	NULL	the investigational product is called supplement
258	2024-03-04 07:46:26	2024-03-04 07:46:30	NCT02745353	Couldn&#x27;t enough accrue patients	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
259	2024-03-04 07:46:33	2024-03-04 07:46:37	NCT02368691	Lack of Efficacy	1c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
260	2024-03-04 07:46:40	2024-03-04 07:46:44	NCT01390584	slow accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
261	2024-03-04 07:46:47	2024-03-04 07:46:50	NCT01683747	Lower than anticipated enrollment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
262	2024-03-04 07:46:54	2024-03-04 07:46:57	NCT01829347	Due to results from the VTI-208 study, the ELAD plan is being re-evaluated.	1d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
263	2024-03-04 07:47:00	2024-03-04 07:47:03	NCT02354092	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
264	2024-03-04 07:47:07	2024-03-04 07:47:10	NCT02605824	The study was closed after we determined that this albuterol&#x2F;NAC regimen may be associated with excessive bronchoconstriction.	1a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
265	2024-03-04 07:47:13	2024-03-04 07:47:17	NCT01545648	Low Accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
266	2024-03-04 07:47:20	2024-03-04 07:47:25	NCT00632827	Manufacturing shortage of both Diftitox and Doxil	2d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
267	2024-03-04 07:47:31	2024-03-04 07:48:08	NCT01641601	Inadequate enrollment. Key study personnel transitioned to a different role.	2a	0	0	0	0	NULL	0	0	0	0	1	0	0	0	NULL
268	2024-03-04 07:48:12	2024-03-04 07:48:16	NCT02567448	Failed to accrue	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
269	2024-03-04 07:48:20	2024-03-04 07:48:22	NCT01821443	Loss of funding	2b	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
270	2024-03-04 07:48:26	2024-03-04 07:48:29	NCT01709474	Due to slow enrollment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
271	2024-03-04 07:48:33	2024-03-04 07:50:07	NCT02307552	The probe could not be anchored in place and would rotate about its axis, thus comparison was difficult.	2d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
272	2024-03-04 07:50:28	2024-03-04 07:50:31	NCT01721603	Low accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
273	2024-03-04 07:50:34	2024-03-04 07:50:37	NCT01780636	POOR RECRUITMENT	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
274	2024-03-04 07:50:39	2024-03-11 09:01:01	NCT02294981	Protocol was changed to make it easier for treating doctors. No safety concerns	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	I find it a bit weird that they did not continue with the trial with a protocol change; 4 patients were included to find the best dosage for excimer laser phototherapy; this is an early phase study to find the right dosage
275	2024-03-04 07:51:14	2024-03-04 07:51:30	NCT02524106	Industry won&#x27;t be moving forward with production of bococizumab	2d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
276	2024-03-04 07:51:54	2024-03-04 07:51:57	NCT01211756	Break in funding	2b	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
277	2024-03-04 07:52:01	2024-03-04 07:52:04	NCT02672033	slow enrollment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
278	2024-03-04 07:52:08	2024-03-04 07:52:13	NCT01046773	Low enrollment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
279	2024-03-04 07:52:19	2024-03-04 07:52:23	NCT01773746	Poor Recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
280	2024-03-04 07:52:27	2024-03-04 07:52:32	NCT01617291	A similar study was recently published with definitive results.	1d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
281	2024-03-04 07:52:36	2024-03-04 07:52:39	NCT01737593	Interim analysis revealed a negative effect.	1a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
282	2024-03-04 07:52:43	2024-03-11 08:58:21	NCT01943188	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
283	2024-03-04 07:52:50	2024-03-11 08:56:49	NCT02381392	Insufficient enrollment, investigator left institution	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	NULL
284	2024-03-04 07:52:57	2024-03-04 07:53:38	NCT01290523	Off study clinical use of Y90 glass microspheres (TheraSphere)	1d	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
285	2024-03-04 07:53:42	2024-03-04 07:53:45	NCT01778855	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
286	2024-03-04 07:53:48	2024-03-04 07:54:18	NCT01502761	No safety issues. Low enrollment secondary to negative stroke studies 2013	1d	0	0	0	0	NULL	1	0	0	0	0	0	0	0	NULL
287	2024-03-04 07:54:21	2024-03-04 07:54:24	NCT00610467	Slow accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
288	2024-03-04 07:54:27	2024-03-04 07:54:31	NCT02170298	Lack of enrollment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
289	2024-03-04 07:54:35	2024-03-04 07:54:47	NCT01402544	Per study sponsor decision.	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
290	2024-03-04 07:54:51	2024-03-04 07:54:53	NCT00751101	Low Accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
291	2024-03-04 07:54:57	2024-03-04 07:54:59	NCT02728700	Accrual factor	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
292	2024-03-04 07:55:03	2024-03-04 07:55:06	NCT01615042	Lack of enrollment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
293	2024-03-04 07:55:10	2024-03-04 07:55:13	NCT01138553	Inadequate subject accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
294	2024-03-04 07:55:23	2024-03-11 08:57:17	NCT02280395	Company merger resulted in business decision to terminate the study.	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
295	2024-03-11 08:08:54	2024-03-11 08:09:58	NCT01826305	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
296	2024-03-11 08:10:03	2024-03-11 08:10:08	NCT02450201	Low accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
297	2024-03-11 08:10:18	2024-03-11 08:10:23	NCT01695473	Lack of Accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
298	2024-03-11 08:10:26	2024-03-11 08:10:30	NCT01442714	Lack of efficacy - Inability to meet the primary response endpoint	1c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
299	2024-03-11 08:10:34	2024-03-11 08:10:39	NCT01055028	Poor accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
300	2024-03-11 08:10:45	2024-03-11 08:10:48	NCT02206776	poor tolerability and low enrollment rate	1a	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL
301	2024-03-11 08:10:52	2024-03-11 08:10:58	NCT01719861	Lack of efficacy	1c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
302	2024-03-11 08:11:02	2024-03-11 08:11:08	NCT01965002	Accrual factor	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
303	2024-03-11 08:11:11	2024-03-11 08:11:15	NCT02855086	logistics	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
304	2024-03-11 08:11:19	2024-03-11 08:11:22	NCT02736578	Logistics	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
305	2024-03-11 08:11:25	2024-03-11 08:14:01	NCT02757547	Business decision to discontinue development of this investigational device.	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	could alternatively be administrative, logistical or technical issues. 
306	2024-03-11 08:14:07	2024-03-11 08:14:25	NCT01034514	business decision	2e	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
307	2024-03-11 08:14:29	2024-03-11 08:14:36	NCT01094587	Enrollment difficulty	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
308	2024-03-11 08:14:41	2024-03-11 08:14:47	NCT01123005	Logistical	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
309	2024-03-11 08:14:54	2024-03-11 08:14:58	NCT01987375	logistics	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
310	2024-03-11 08:15:01	2024-03-11 08:15:06	NCT01067144	Trial met futility stopping point	1c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
311	2024-03-11 08:15:13	2024-03-11 08:15:20	NCT02586415	Interim analysis showed a high likelihood of benefit in the endovascular group	1b	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
312	2024-03-11 08:15:22	2024-03-11 08:15:27	NCT02303041	Business Decision	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
313	2024-03-11 08:15:31	2024-03-11 08:15:35	NCT01020812	enrollment was too low	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
314	2024-03-11 08:15:38	2024-03-11 08:15:42	NCT01506726	Study drug expiration and supply shortage	2d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
315	2024-03-11 08:15:46	2024-03-11 08:15:58	NCT01868503	Protocol modification	3b	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	the reason for protocol modification is not mentioned
316	2024-03-11 08:16:01	2024-04-15 07:43:09	NCT01406795	Poor enrollment and advances in venoplasty only techniques of the femoral vein	1d	0	0	0	0	0	1	0	0	0	0	0	0	0	NULL
317	2024-03-11 08:18:28	2024-03-11 08:24:01	NCT01313884	Study did not reach primary objective; study did not accrue enough patients.	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL	NULL
318	2024-03-11 08:24:29	2024-03-11 08:24:32	NCT01893879	insufficient enrollment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
319	2024-03-11 08:24:35	2024-03-11 08:24:38	NCT01928030	Low accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
320	2024-03-11 08:24:42	2024-03-11 08:24:46	NCT01364259	Patterns of practice changed and this technique is no longer used.	1d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
321	2024-03-11 08:24:50	2024-03-11 08:24:54	NCT01769222	Planned Future Study	3b	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
322	2024-03-11 08:24:58	2024-03-11 08:25:06	NCT03023709	Due to the ACIP guidelines halting the use of LAIV	1d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
323	2024-03-11 08:25:11	2024-03-11 08:25:14	NCT01823679	Low accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
324	2024-03-11 08:25:18	2024-03-11 08:32:07	NCT02030405	Regulatory	1a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	not sure, but a regulatory decision most oftenly is a scientific decision. it is a phase 2 study, it could also just mean that enough data has been collected; there were other cases which I categorized as evidence of benefit
325	2024-03-11 08:32:10	2024-03-11 08:32:14	NCT02175745	Re-evaluate indication with the referring physicians	3b	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
326	2024-03-11 08:32:20	2024-03-11 08:32:24	NCT03028987	LAIV was no longer recommended by ACIP	1d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
327	2024-03-11 08:32:27	2024-03-11 08:32:32	NCT00481832	Accrual Factor	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
328	2024-03-11 08:32:37	2024-03-11 08:32:41	NCT02877732	The funding sponsor elected to terminate the study.	2b	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
329	2024-03-11 08:32:45	2024-03-11 08:32:49	NCT02415608	Slow accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
330	2024-03-11 08:32:54	2024-03-11 08:32:57	NCT01846624	Accrual factor	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
331	2024-03-11 08:33:00	2024-03-11 08:33:05	NCT03206216	Business decision	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
332	2024-03-11 08:33:08	2024-03-11 08:33:11	NCT01472445	Slow accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
333	2024-03-11 08:33:15	2024-03-11 08:33:19	NCT00568633	Poor accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
334	2024-03-11 08:33:23	2024-03-11 08:33:28	NCT03061279	Problem negotiating other sites	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
335	2024-03-11 08:33:32	2024-03-11 08:33:36	NCT01745354	Accrual issues - Slow accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
336	2024-03-11 08:33:40	2024-03-11 08:33:44	NCT01857752	accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
337	2024-03-11 08:33:47	2024-03-11 08:33:51	NCT01904643	Accrual factor	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
338	2024-03-11 08:33:55	2024-03-11 08:33:58	NCT02075190	Dr. Gyurak is no longer doing and ended her NARSAD early.	2c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
339	2024-03-11 08:34:01	2024-04-15 07:44:19	NCT02436460	Re-initiate a new trial per the discussion with FDA	1e	0	0	0	0	NULL	0	0	0	0	0	0	0	1	scientific reason but difficult to pinpoint
340	2024-03-11 08:44:55	2024-03-11 08:45:12	NCT02042157	Equipment malfunction.	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
341	2024-03-11 08:45:18	2024-03-11 08:45:22	NCT02890875	Low recruitment	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
342	2024-03-11 08:45:29	2024-03-11 08:45:33	NCT01188486	Business decision	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
343	2024-03-11 08:45:38	2024-03-11 08:45:42	NCT02429804	Accrual factor	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
344	2024-03-11 08:45:45	2024-03-11 08:45:49	NCT02435225	Change in goals of PI	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
345	2024-03-11 08:45:55	2024-03-11 08:46:00	NCT02708511	[No reason posted]	3a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
346	2024-03-11 08:46:04	2024-03-11 08:46:08	NCT02049801	logistics	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
347	2024-03-11 08:46:12	2024-03-11 08:46:15	NCT02635074	safety	1a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
348	2024-03-11 08:46:19	2024-03-11 08:47:57	NCT01192776	The trial closed for emerging safety profile and futility analysis and will not resume.	1a	0	0	1	0	NULL	0	0	0	0	0	0	0	0	NULL
349	2024-03-11 08:48:00	2024-03-11 08:48:07	NCT01954082	Study terminated due to safety concerns; participant follow up will continue until March 2018	1a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
350	2024-03-11 08:48:10	2024-03-11 08:48:16	NCT01614652	Company is closed	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
351	2024-03-11 08:48:20	2024-03-11 08:48:28	NCT02057991	Insufficient Accrual	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
352	2024-03-11 08:48:31	2024-03-11 08:48:35	NCT03115385	Funds ended.	2b	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
353	2024-03-11 08:48:39	2024-03-11 08:48:43	NCT01302405	closing due to low enrollment, no safety issues	2a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
354	2024-03-11 08:48:46	2024-03-11 08:48:51	NCT01153919	Approval of several new agents for the treatment of HCV infection would mitigate the future need for interferon HCV treatment	1d	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
356	2024-03-11 08:49:04	2024-03-11 08:49:15	NCT01238965	Adverse Events	1a	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
358	2024-03-11 08:49:43	2024-03-11 08:49:54	NCT01469338	lack of funding	2b	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
360	2024-03-11 08:50:55	2024-03-11 08:51:12	NCT02270684	Recruitment and retention difficulties	2a	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
361	2024-03-11 08:51:16	2024-03-11 08:51:39	NCT01866423	Not progressing toward scientific goals	1c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	Phase 2 trial, could aslo be evidence of harm
363	2024-03-11 08:52:23	2024-03-11 08:52:40	NCT02370264	Study not progressing toward scientific goals	1c	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	NULL
365	2024-03-11 08:52:54	2024-03-11 08:53:38	NCT03104816	Could not get an approval from Department Reviewer for the study continuation.	2e	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	NULL	1	seems like it is an internal department reviewer who can decide about study continuation
366	2024-03-11 08:53:41	2024-03-11 08:53:46	NCT01649258	Lack of Efficacy	1c	0	0	0	0	NULL	0	0	0	0	0	0	0	1	NULL
